Premium
HLA genotyping meets response to immune checkpoint inhibitors prediction: A story just started
Author(s) -
Ivanova Milena,
Shivarov Velizar
Publication year - 2021
Publication title -
international journal of immunogenetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.41
H-Index - 47
eISSN - 1744-313X
pISSN - 1744-3121
DOI - 10.1111/iji.12517
Subject(s) - human leukocyte antigen , immune checkpoint , immunoediting , genotyping , blockade , immune system , immunology , germline , immunotherapy , biology , medicine , genetics , antigen , genotype , gene , receptor
The implementation of the immune checkpoint blockade as a therapeutic option in contemporary oncology is one of the significant immunological achievements in the last century. Constantly accumulating evidence suggests that the response to immune checkpoint inhibitors (ICIs) is not universal. Therefore, it is critical to identify determinants for response, resistance and adverse effects of immune checkpoint therapy that could be developed as prognostic and predictive markers. Recent large scale analyses of cancer genome data revealed the key role of HLA class I and class II molecules in cancer immunoediting, and it appears that HLA diversity can predict response to ICIs. In the present review, we summarize the emerging data on the role of HLA germline variations as a marker for response to ICIs.